Physician profile
Jesse Martin Vislisel
NPI 1063704294
$4,145.36
in general payments reported to CMS, 2019-2025
11 companies · $20.47 in 2025
The $20.47 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,551 · 2020: $19.88 · 2021: $72.74 · 2022: $118 · 2023: $1,304 · 2024: $59.41 · 2025: $20.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,225 · Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,225.00 |
| Food and Beverage | $159.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,097.13 | 2019-2023 | Acrysof Iq Vivity, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $1,500.00 | 2019 | |
| Alcon Research LLC | $245.00 | 2023 | |
| Oyster Point Pharma, INC. | $88.41 | 2022-2024 | Tyrvaya |
| Topcon Healthcare Solutions, INC. | $80.24 | 2022 | |
| Ocular Therapeutix, INC. | $50.00 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $29.67 | 2023-2024 | Acuvue |
| Harrow Eye, LLC | $20.47 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $14.56 | 2024 | Xdemvy |
| The Cameron-Ehlen Group, INC. | $13.38 | 2020 | |
| Biotissue Holdings INC. | $6.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Vislisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.